SCHEMBL3878672

SCHEMBL3878672

Cn1c(=O)[nH]c2c(N3CCN(C(=O)OC(C)(C)C)CC3)nc(Cl)nc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 2/20 0.40
PIK3CD O00329 1/20 0.40
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
MAP4K4 O95819 1/20 0.38
GAA P10253 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GBA1 P04062 2/20 0.37
POLB P06746 1/20 0.37
CKS1B P61024 1/20 0.37
SKP1 P63208 1/20 0.37
SKP2 Q13309 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KCNH2 Q12809 1/20 0.37
TLR9 Q9NR96 1/20 0.37
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OGFRL1 Q5TC84 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13876130 0.82 KIT (0.35) KITPIK3CDCNR1CNR2GBA1
SCHEMBL1695032 0.82 OPRM1 (0.42) KITPIK3CDCNR1CNR2OPRM1
SCHEMBL3874202 0.81 KIT (0.52) KITPIK3CDCNR1CNR2MAP4K4
SCHEMBL13876131 0.80 KIT (0.43) KITPIK3CDCNR1CNR2GBA1
SCHEMBL3888718 0.79 CNR1 (0.44) KITCNR1CNR2MAP4K4GBA1
SCHEMBL20011912 0.76 POLB (0.47) KITCNR1CNR2MAP4K4GBA1
SCHEMBL30060994 0.76 POLB (0.47) KITCNR1CNR2MAP4K4GBA1
SCHEMBL13876125 0.76 BTK (0.48) MAP4K4
SCHEMBL12517586 0.75 DDB1 (0.43) KITMAP4K4POLBCKS1BSKP1
SCHEMBL3885854 0.75 PIK3CD (0.45) KITPIK3CDCNR1CNR2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7524847-B2 Fused 1,3-dihydro-imidazole ring compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-04-28 US disclosed
US-7524847-B2 Fused 1,3-dihydro-imidazole ring compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-04-28 US disclosed
US-7524847-B2 Fused 1,3-dihydro-imidazole ring compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-04-28 US disclosed
CN-100376573-C Fused 1, 3-dihydro-imidazole ring compounds EISAI CO LTD (JP) 2008-03-26 CN disclosed
US-20060111362-A1 1,3-Dihydroimidazole ring compound EISAI CO., LTD. (JP) 2006-05-25 US disclosed
CN-1745080-A 1,3-dihydroimidazole fused-ring compound EISAI CO LTD (JP) 2006-03-08 CN disclosed
EP-1568699-A1 1,3-DIHYDROIMIDAZOLE FUSED-RING COMPOUND Eisai Co., Ltd. (JP) 2005-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111362-A1 1,3-Dihydroimidazole ring compound NR2C2, NR0B2, DPP4 KIT 4046/4885PIK3CD 4371/4885CNR1 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.